公开(公告)号：US20120058983A1

公开(公告)日：2012-03-08

申请号：US13210889

申请日：2011-08-16

Applicant: Jürgen Klar ,  Georges VON DEGENFELD ,  Hans-Georg LERCHEN ,  Barbara Albrecht-Küpper ,  Andreas KNORR ,  Peter SANDNER ,  Daniel MEIBOM

Inventor： Jürgen Klar ,  Georges VON DEGENFELD ,  Hans-Georg LERCHEN ,  Barbara Albrecht-Küpper ,  Andreas KNORR ,  Peter SANDNER ,  Daniel MEIBOM

IPC: A61K31/4439 ,  A61P27/06 ,  A61P27/02 ,  C07D417/12

CPC classification number: A61K31/4439 ,  A61K9/0048 ,  A61K9/08 ,  A61K38/05 ,  A61K45/06 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.

Abstract translation: 本发明涉及选择性腺苷A1激动剂，特别是式（I）的二氰基吡啶用于治疗和/或预防青光眼和高眼压症及其用于生产治疗药物的用途的用途 和/或预防青光眼和高眼压症。

公开(公告)号：US09040566B2

公开(公告)日：2015-05-26

申请号：US13819790

申请日：2011-08-29

Applicant: Jürgen Klar ,  Georges Von Degenfeld ,  Hans-Georg Lerchen ,  Barbara Albrecht-Küpper ,  Andreas Knorr ,  Peter Sandner ,  Daniel Meibom

Inventor： Jürgen Klar ,  Georges Von Degenfeld ,  Hans-Georg Lerchen ,  Barbara Albrecht-Küpper ,  Andreas Knorr ,  Peter Sandner ,  Daniel Meibom

IPC: A01N43/40 ,  A61K31/44 ,  C07D409/00 ,  C07D411/00 ,  C07D405/00 ,  C07D417/12 ,  A61K9/00 ,  A61K9/08 ,  A61K31/4439 ,  A61K45/06 ,  C07D413/12 ,  C07D417/14

CPC classification number: A61K31/4439 ,  A61K9/0048 ,  A61K9/08 ,  A61K38/05 ,  A61K45/06 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.

Abstract translation: 本发明涉及选择性腺苷A1激动剂，特别是式（I）的二氰基吡啶用于治疗和/或预防青光眼和高眼压症及其用于生产治疗药物的用途的用途 和/或预防青光眼和高眼压症。

公开(公告)号：US20130035340A1

公开(公告)日：2013-02-07

申请号：US13577135

申请日：2011-02-03

Applicant: Peter Sandner ,  Georges Von Degenfeld ,  Johannes-Peter Stasch

Inventor： Peter Sandner ,  Georges Von Degenfeld ,  Johannes-Peter Stasch

IPC: A61K31/53 ,  A61P11/00

CPC classification number: A61K45/06 ,  A61K31/18 ,  A61K31/194 ,  A61K31/427 ,  A61K31/4418 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  A61K2300/00

Abstract: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment of Cystic Fibrosis (CF).

Abstract translation: 本发明涉及可溶性鸟苷酸环化酶（sGC）和磷酸二酯酶（PDEs）以及sGC刺激剂，sGC激活剂和PDE抑制剂的药理学。 更具体地，本发明涉及sGC刺激剂和sGC激活剂与PDE5抑制剂组合用于制备用于治疗囊性纤维化（CF）的药物的用途。

公开(公告)号：US20100184769A1

公开(公告)日：2010-07-22

申请号：US12664396

申请日：2008-05-31

Applicant: Peter SANDNER

Inventor： Peter SANDNER

IPC: A61K31/53 ,  C07D487/04 ,  A61P27/16 ,  C12Q1/42

CPC classification number: C12Q1/44 ,  A61K31/53 ,  G01N2333/916 ,  G01N2500/04 ,  G01N2800/14

Abstract: The invention provides pharmacological compositions comprising PDE-5 inhibitors for the treatment of hearing impairment i.e. hearing loss and tinnitus. The invention also provides methods of screening for such PDE-5 inhibitors for use in the preparation of medicaments for the treatment of hearing impairment i.e. hearing loss and tinnitus.

Abstract translation: 本发明提供包含PDE-5抑制剂用于治疗听力损伤（即听力损失和耳鸣）的药物组合物。 本发明还提供了筛选用于制备用于治疗听力损害（即听力损失和耳鸣）的药物的这种PDE-5抑制剂的方法。

公开(公告)号：US20100035888A1

公开(公告)日：2010-02-11

申请号：US12084662

申请日：2006-10-30

Applicant: Peter Sandner ,  Hanna Tinel ,  Joachim Hütter ,  Bernd Riedl ,  Martina Klein

Inventor： Peter Sandner ,  Hanna Tinel ,  Joachim Hütter ,  Bernd Riedl ,  Martina Klein

IPC: A61K31/4412 ,  A61K31/496 ,  A61K31/519 ,  A61K31/506 ,  A61P7/00

CPC classification number: A61K31/435 ,  Y02A50/423

Abstract: The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.

Abstract translation: 本发明涉及用于治疗，预防或控制肺动脉高压的药物组合物，其包含任选组合的4- {3- [4-（3-氯苯基） 与至少一种另外的治疗剂。

公开(公告)号：US20100010024A1

公开(公告)日：2010-01-14

申请号：US12307126

申请日：2007-06-25

Applicant: Franz Von Nussbaum ,  Heike Gielen-Haertwig ,  Martin Klein ,  Volkhart Min-Jian Li ,  Daniel Meibom ,  Peter Sandner ,  Klemens Lustig ,  Stefan Schäfer

Inventor： Franz Von Nussbaum ,  Heike Gielen-Haertwig ,  Martin Klein ,  Volkhart Min-Jian Li ,  Daniel Meibom ,  Peter Sandner ,  Klemens Lustig ,  Stefan Schäfer

IPC: A61K31/513 ,  C07D239/22 ,  C07D401/04 ,  A61K31/506 ,  A61P9/12

CPC classification number: C07D239/22 ,  A61K31/506 ,  A61K31/513 ,  A61K45/06 ,  C07D401/04

Abstract: The present application relates to the use of 1,4-diaryldihydropyrimidin-2-one derivatives of the formula (I) for the treatment and/or prophylaxis of pulmonary arterial hypertension and other types of pulmonary hypertension, and to the use thereof for the manufacture of medicaments for the treatment and/or prophylaxis of pulmonary arterial hypertension and other types of pulmonary hypertension.

Abstract translation: 本申请涉及式（I）的1,4-二芳基二氢嘧啶-2-酮衍生物用于治疗和/或预防肺动脉高压和其他类型的肺动脉高压的用途及其用于制造的用途 用于治疗和/或预防肺动脉高压和其他类型的肺动脉高压的药物。

公开(公告)号：US20090186896A1

公开(公告)日：2009-07-23

申请号：US11992779

申请日：2006-09-16

Applicant: Ernst Ulbrich ,  Peter Sandner ,  Hanna Tinel ,  Joachim Hütter

Inventor： Ernst Ulbrich ,  Peter Sandner ,  Hanna Tinel ,  Joachim Hütter

IPC: A61K31/501 ,  G01N33/566 ,  A61K31/497 ,  A61K31/506 ,  A61P15/10

CPC classification number: C12Q1/44 ,  G01N2500/00

Abstract: The invention provides pharmacological compositions comprising PDE-5 and PDE-4 inhibitors, alone or in combination, for the treatment of urological disorders comprising Benign Prostate Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS) and in particular irritative symptoms caused by BPH-induced bladder outlet obstruction (BOO). The invention also provides methods of screening for such PDE-5 and PDE-4 inhibitors for use, alone and in combination, in the preparation of medicaments for the treatment of said urological disorders.

Abstract translation: 本发明提供包含单独或组合的PDE-5和PDE-4抑制剂的药物组合物，用于治疗包括良性前列腺增生（BPH），下尿路症状（LUTS）的泌尿系统疾病，特别是由BPH引起的刺激性症状 引起膀胱出口阻塞（BOO）。 本发明还提供筛选此类PDE-5和PDE-4抑制剂的方法，其用于单独或组合用于治疗所述泌尿系疾病的药物的制备。

公开(公告)号：US20080214654A1

公开(公告)日：2008-09-04

申请号：US11665316

申请日：2005-10-12

Applicant: Thomas Lampe ,  Cristina Alonso-Alija ,  Beatrix Stelte-Ludwig ,  Peter Sandner ,  Marcus Bauser ,  Hartmut Beck ,  Klemens Lustig ,  Ulrich Rosentreter ,  Elke Stahl ,  Hiroko Takagi

Inventor： Thomas Lampe ,  Cristina Alonso-Alija ,  Beatrix Stelte-Ludwig ,  Peter Sandner ,  Marcus Bauser ,  Hartmut Beck ,  Klemens Lustig ,  Ulrich Rosentreter ,  Elke Stahl ,  Hiroko Takagi

IPC: A61K31/381 ,  C07C271/06 ,  A61K31/27 ,  A61K31/164 ,  A61P13/02 ,  C07C237/00 ,  C07D333/02

CPC classification number: C07C233/40 ,  C07C233/36 ,  C07C233/37 ,  C07C233/38 ,  C07C233/62 ,  C07C233/73 ,  C07C233/78 ,  C07C271/20 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/10 ,  C07D231/14 ,  C07D333/38

Abstract: The present invention relates to novel substituted benzyloxy-phenylmethylamide derivatives, processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold Menthol Receptor 1 (CMR-1) activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

Abstract translation: 本发明涉及新的取代的苄氧基 - 苯基甲基甲酰胺衍生物，其制备方法及其在药物中的用途，特别是用于预防和治疗与冷薄荷醇受体1（CMR-1）活性有关的疾病，特别是用于治疗 泌尿系统疾病或障碍，如逼尿肌过度活动症（膀胱过度活动症），尿失禁，神经源性逼尿肌过敏反应（逼尿肌过敏症），特发性逼尿肌过度活动（逼尿肌不稳定），良性前列腺增生和下尿路症状; 慢性疼痛，神经性疼痛，术后疼痛，类风湿性关节炎疼痛，神经痛，神经病，痛觉，神经损伤，局部缺血，神经变性，中风和炎性疾病如哮喘和慢性阻塞性肺（或气道）疾病（COPD）。